FDA Approves First Oral PCSK9 Inhibitor to Treat High Cholesterol

The FDA has officially approved Merck's Lipfendra (enlicitide), marking a major milestone in cardiovascular medicine: the first oral medication in a highly effective class of cholesterol-lowering drugs known as PCSK9 inhibitors.[1]

Until now, patients requiring this advanced level of intervention had to rely on subcutaneous injections, a barrier that has severely limited the adoption of these life-saving therapies over the past decade.[3][4]

The approval introduces a 20-milligram, once-daily tablet designed to be used alongside diet and exercise for adults with hypercholesterolemia, including those with a genetic condition called heterozygous familial hypercholesterolemia (HeFH).[5]

By converting a complex biologic mechanism into a daily pill, the pharmaceutical industry has solved one of the most persistent delivery challenges in modern cardiology, offering a new lifeline to patients who cannot achieve safe lipid levels with standard statins.[4][6]

To understand why this approval is considered a breakthrough, it is necessary to examine the mechanism of PCSK9—a protein synthesized in the liver that plays a critical role in cholesterol regulation.[2]

The liver clears low-density lipoprotein (LDL), commonly known as "bad" cholesterol, from the bloodstream using specialized LDL receptors on the surface of its cells.[2]

However, the PCSK9 protein naturally binds to these receptors and marks them for degradation, actively reducing the liver's ability to pull cholesterol out of the blood.[2]

PCSK9 inhibitors work by blocking this protein, thereby preserving the LDL receptors and allowing the liver to continuously scrub cholesterol from circulation.[2][5]

The first drugs in this class, such as Amgen's Repatha and Sanofi/Regeneron's Praluent, were approved in 2015 and proved astonishingly effective, but because they were large monoclonal antibodies, they had to be injected every two to four weeks.[2][3]

Lipfendra achieves the same biological blockade using a novel "macrocyclic peptide"—a smaller, specially engineered molecule that can survive the harsh environment of the digestive tract and enter the bloodstream without being destroyed.[5]

The clinical evidence supporting the FDA's decision stems from the Phase 3 CORALreef trial program, which demonstrated efficacy mirroring that of the drug's injectable predecessors.[5]

In the CORALreef Lipids trial, which included nearly 3,000 participants at high risk for cardiovascular events, Lipfendra reduced LDL cholesterol by a placebo-adjusted 56 percent over 24 weeks.[5]

A parallel trial focusing on patients with the inherited HeFH condition showed an even steeper 59 percent reduction, with the drug's safety profile remaining comparable to a placebo, aside from mild increases in diarrhea and dizziness.[3]

Despite the impressive clinical data, the transition from an injection to a pill introduces a significant new variable: a highly restrictive daily dosing regimen.[3]

Because the peptide is highly sensitive to food interactions, patients must take Lipfendra in the morning following an eight-hour fast, and then wait an additional 30 minutes before consuming any food or beverages.[2][3]

Clinical skeptics warn that this strict schedule could lead to poor adherence, potentially undermining the drug's real-world effectiveness compared to a biweekly or monthly injection administered by a professional or taken with a simple auto-injector.[3][4]

Cost and access, however, represent a major advantage for the new oral therapy, addressing the primary reason injectable PCSK9 inhibitors have historically struggled to reach a broad patient population.[4][6]

Merck has set the list price for Lipfendra at $315 per month—roughly half the cost of existing injectable options—and plans to distribute the drug directly to consumers through direct-to-patient pharmacy channels to bypass traditional benefit hurdles.[2][3]

While the drug's ability to lower cholesterol is now undisputed, the medical community is still awaiting the results of the ongoing CORALreef Outcomes trial, which is tracking 14,500 patients to confirm whether the pill definitively prevents heart attacks and strokes.[4][5]

As competitors like AstraZeneca race to develop their own oral candidates, the approval of Lipfendra signals a new era in lipid management, expanding access to a potent class of drugs that could alter the trajectory of global cardiovascular disease.[3]